Poor mobilizer: A retrospective study on proven and predicted incidence according to GITMO criteria

Piccirillo, Nicola; Vacca, Michele; Lanti, Alessandro; Ipsevich, Francesco; Maresca, Maddalena; Fiorelli, Elena; Bianchi, Maria; Adorno, Gaspare; Pierelli, Luca; Majolino, Ignazio; Leone, Giuseppe; Zini, Gina

doi:10.1016/j.transci.2012.06.008

Cited by 14 publications

(14 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On further analysis for median CD34+ cell yield, older age and the need to administer plerixafor were associated with a relatively poor collection. Various studies have identified lenalidomide exposure, older age, prior chemotherapy including alkylating agents, extensive marrow involvement of myeloma, and prior radiation therapy affecting the marrow as predictors of poor PBSC mobilization . Our results were consistent with those earlier reports, regardless of the chemotherapy regimen used.…”

Section: Discussionsupporting

confidence: 92%

“…Various studies have identified lenalidomide exposure, older age, prior chemotherapy including alkylating agents, extensive marrow involvement of myeloma, and prior radiation therapy affecting the marrow as predictors of poor PBSC mobilization. 5,7,8 Our results…”

Section: Discussionsupporting

confidence: 55%

“…Approximately 5‐40% patients fail to mobilize adequate PBSC, and require plerixafor‐ or a chemotherapy‐based mobilization regimen to aid in PBSC collection . Poor mobilizers generally include patients with extensive prior therapy with alkylating agents or immunomodulatory drugs or prior radiotherapy to spine or pelvis …”

Section: Introductionmentioning

confidence: 99%

“…5,6 Poor mobilizers generally include patients with extensive prior therapy with alkylating agents or immunomodulatory drugs or prior radiotherapy to spine or pelvis. 7 Chemomobilization generally utilizes single-agent cyclophosphamide with filgrastim, and has been shown to improve CD34+ cell yield for multiple myeloma patients. 6,8 High-dose Cy is given at a dose of 2-4 g/m 2 with filgrastim, although an optimal chemomobilization regimen has not been defined.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Modified CVAD and modified CBAD compared to high‐dose cyclophosphamide for peripheral blood stem cell mobilization in patients with multiple myeloma

Gettys

Gulbis

Wilhelm

et al. 2017

European J of Haematology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 55%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Modified CVAD and modified CBAD compared to high‐dose cyclophosphamide for peripheral blood stem cell mobilization in patients with multiple myeloma

Gettys

Gulbis

Wilhelm

et al. 2017

European J of Haematology

View full text Add to dashboard Cite

show abstract

“…Approximately 15% of all patients are considered to be PMs. 7,23 Even for some patients with CD34+ levels of more than 20 × 10 6 /L in PB it is difficult to collect an adequate graft for a second transplantation. We defined these patients as inadequate mobilizers (IMs).…”

Section: Introductionmentioning

confidence: 99%

Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma

et al. 2014

View full text Add to dashboard Cite

BACKGROUND:Harvest of more than one CD34+ stem cell transplant has become the standard, to ensure the option for a second autologous transplantation in patients with relapsed or progressive multiple myeloma (MM). Additional administration of the CXCR-4 inhibitor plerixafor has been shown to increase the efficiency of CD34+ stem cell harvest. However, the algorithm when to apply plerixafor is still under debate. STUDY DESIGN AND METHODS:In this retrospective study, 46 MM patients were categorized into four groups according to their CD34+ stem cell count in peripheral blood (PB) and mobilization with or without plerixafor: Group A comprised poor mobilizers with CD34+ cell counts of fewer than 20 × 10 6 /L in PB. Group B included inadequate mobilizers with CD34+ cell counts of 20 × 10 6 /L or more in PB and a low CD34+ stem cell yield in the first leukapheresis session. Patients receiving plerixafor preemptively (Group A1) and as a rescue strategy (Group B1) were compared to patients continuing stem cell collection with granulocyte-colony-stimulating factor alone (Groups A2 and B2). RESULTS: In both, the preemptive and the rescue settings, plerixafor enhanced the CD34+ stem cell yield significantly. Poor mobilization and administration of plerixafor was not associated with delayed engraftment. CONCLUSION: Our data demonstrate that administration of plerixafor is safe and effective and facilitates a significantly higher CD34+ stem cell harvest. Based on the presented data, we propose an algorithm for the use of plerixafor for CD34+ stem cell mobilization and harvesting in poor mobilizing myeloma patients.

show abstract

Stem cell mobilization in lymphoma patients

Ballinger¹,

Savani²,

Mohty³

2015

Clinical Guide to Transplantation in Lymphoma

View full text Add to dashboard Cite

Poor mobilizer: A retrospective study on proven and predicted incidence according to GITMO criteria

Cited by 14 publications

References 28 publications

Modified CVAD and modified CBAD compared to high‐dose cyclophosphamide for peripheral blood stem cell mobilization in patients with multiple myeloma

Modified CVAD and modified CBAD compared to high‐dose cyclophosphamide for peripheral blood stem cell mobilization in patients with multiple myeloma

Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma

Stem cell mobilization in lymphoma patients

Contact Info

Product

Resources

About